ESMO 2020: Nivolumab plus Cabozantinib Outperforms Sunitinib in Advanced Renal Cell Carcinoma
Study authors suggest the combination be considered a first-line option
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.